Wells Fargo Upgrades Viridian Therapeutic (VRDN) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts VRDN Hot Sheet
Price: $25.15 --0%
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Derek Archila upgraded Viridian Therapeutic (NASDAQ: VRDN) from Equal Weight to Overweight with a price target of $31.00.
For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.
Shares of Viridian Therapeutic closed at $17.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies on ArcBest (ARCB): 'The quarter was a solid beat' (correction)
- Blackwells backs Braemar Hotels' eight director nominees for 2026 vote
- Ondas wins counter-drone contracts in Europe and Asia
Create E-mail Alert Related Categories
UpgradesRelated Entities
Wells Fargo, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
